We are one of the largest and most advanced liver cancer treatment programs in the world. We take the newest innovations in immune and targeted therapies and achieve unparalleled results.

They told me I was off the liver transplant list. I was devastated. I got a new combination of drugs and now, 15 months later, I'm back on the list. This program saved my life.

P.K. Stage IV liver cancer 2019

Decade long history of firsts

  • Participated in the first trials of trebananib (2010)

  • Participated in the first trials of tivantinib (2010)

  • First to use cabozantinib (2012)

  • First to use dual tyrosine kinase inhibitors (2012).

  • First to use pembrolizumab with sorafenib (2016)

  • First to use nivolumab and regorafenib (2018)

  • First to use lenvatinib and cabozantinib (2018)

  • First to use nivolumab with lenvatinib and cabozantinib (2018)

  • Discovered an immune marker that predicts response to immunotherapy (2019)